Simulations Plus, Inc. (NASDAQ:SLP) – Investment analysts at Taglich Brothers reduced their Q2 2019 EPS estimates for shares of Simulations Plus in a research report issued to clients and investors on Wednesday, January 16th. Taglich Brothers analyst H. Halpern now forecasts that the technology company will earn $0.10 per share for the quarter, down from their prior forecast of $0.12. Taglich Brothers currently has a “Speculative Buy” rating on the stock. Taglich Brothers also issued estimates for Simulations Plus’ Q4 2019 earnings at $0.09 EPS, FY2019 earnings at $0.43 EPS, Q1 2020 earnings at $0.10 EPS, Q2 2020 earnings at $0.13 EPS, Q3 2020 earnings at $0.20 EPS, Q4 2020 earnings at $0.11 EPS and FY2020 earnings at $0.54 EPS.
Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Wednesday, January 9th. The technology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Simulations Plus had a return on equity of 23.26% and a net margin of 29.05%. The firm had revenue of $7.54 million for the quarter, compared to analyst estimates of $7.45 million.
NASDAQ SLP opened at $19.60 on Friday. Simulations Plus has a 52 week low of $14.25 and a 52 week high of $23.95. The company has a market cap of $335.93 million, a price-to-earnings ratio of 39.20 and a beta of -0.55.
Institutional investors have recently modified their holdings of the company. MetLife Investment Advisors LLC acquired a new position in shares of Simulations Plus in the 2nd quarter valued at $129,000. ClariVest Asset Management LLC purchased a new stake in Simulations Plus in the 3rd quarter valued at $210,000. Citadel Advisors LLC purchased a new stake in Simulations Plus in the 2nd quarter valued at $246,000. Rhumbline Advisers purchased a new stake in Simulations Plus in the 2nd quarter valued at $246,000. Finally, Bank of Montreal Can raised its position in Simulations Plus by 59.8% in the 3rd quarter. Bank of Montreal Can now owns 13,366 shares of the technology company’s stock valued at $270,000 after purchasing an additional 5,004 shares during the last quarter. Institutional investors and hedge funds own 38.40% of the company’s stock.
In other news, Director Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction on Monday, October 29th. The shares were sold at an average price of $20.01, for a total value of $370,185.00. Following the completion of the transaction, the director now owns 5,399,408 shares in the company, valued at approximately $108,042,154.08. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 31.57% of the company’s stock.
The business also recently announced a quarterly dividend, which will be paid on Friday, February 1st. Stockholders of record on Friday, January 25th will be issued a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.22%. The ex-dividend date is Thursday, January 24th. Simulations Plus’s payout ratio is 48.00%.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.